FibroBiologics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25.8%
$FBLG
Biotechnology: Pharmaceutical Preparations
Health Care
FibroBiologics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 25.8%
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $12.00 | Buy | Rodman & Renshaw |
| 10/30/2024 | $12.00 | Buy | H.C. Wainwright |
| 9/24/2024 | $12.00 | Buy | Maxim Group |
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum March 13th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4hnure6 It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "We look forward to bringing together innovators from the life sciences sector," s
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation. HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics") , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts to improve mitochondrial performance in cells. Mitochondria are critical organelles responsible for cellular
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive OfficerHamid Khoja, PhD, Chief Scientific OfficerRobert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiol
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
4 - FibroBiologics, Inc. (0001958777) (Issuer)
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced today it is set to join the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30, ranking them b
HOUSTON, March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the appointment of Ruben A. Garcia as General Counsel. He will report to Pete O'Heeron, FibroBiologics' Founder, Chairman and Chief Executive Officer, and be an integral member of the executive leadership team. "The addition of Ruben as our General Counsel rep
Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
Maxim Group initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00
SCHEDULE 13G - FibroBiologics, Inc. (0001958777) (Subject)
EFFECT - FibroBiologics, Inc. (0001958777) (Filer)
8-K - FibroBiologics, Inc. (0001958777) (Filer)